Showing results (1-10 of 174) with videos related to
Sort By:
Pageof 18
Clinical Breast Cancer|November 19, 2002
The European experience with docetaxel in the treatment of early-stage breast cancerAngelo Di LeoClinical Breast Cancer|September 23, 2003
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?Angelo Di Leo, Jorma IsolaCancer Treatment Reviews|June 15, 2013
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impactNatalie H Turner, Angelo Di LeoNature Reviews. Clinical Oncology|October 27, 2010
Breast cancer assessment tools and optimizing adjuvant therapyCatherine Oakman, Libero Santarpia, Angelo Di LeoBreast (Edinburgh, Scotland)|December 17, 2019
Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancerAmelia McCartney, Matteo Benelli, Angelo Di LeoBreast (Edinburgh, Scotland)|April 13, 2010
Management of triple negative breast cancerCatherine Oakman, Giuseppe Viale, Angelo Di LeoCurrent Opinion in Oncology|September 5, 2014
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapyIlenia Migliaccio, Angelo Di Leo, Luca MalorniThe Lancet. Oncology|July 8, 2015
Continued value of adjuvant anthracyclines as treatment for early breast cancerNatalie Turner, Laura Biganzoli, Angelo Di LeoCurrent Opinion in Oncology|August 29, 2009
Predicting anthracycline benefit: have we made any progress?Erica Moretti, Catherine Oakman, Angelo Di LeoCancer Treatment Reviews|December 10, 2002
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancerFatima Cardoso, Angelo Di Leo, Martine J PiccartPageof 18